Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 9, 2026, with a contested board election involving DOMA Perpetual Capital Management's proxy challenge.

• Strategic direction centers on the 5x30 plan to grow commercial business and diversify the product portfolio by 2030.

• Record 2025 financial performance: $726.4M in revenue, GAAP net income of $7.0M, and non-GAAP net income of $122.3M.

• Key products include EXPAREL, ZILRETTA, and iovera°, with ongoing pipeline investments and international expansion.

• Favorable EXPAREL patent settlement extends exclusivity into 2030, supporting long-term growth.

Voting matters and shareholder proposals

• Shareholders are urged to vote for three board nominees on the BLUE proxy card and disregard DOMA's white proxy card.

• Proxy contest centers on board composition and strategic direction, with DOMA proposing alternative nominees.

Board of directors and corporate governance

• Board refreshed with five independent directors since 2023 and a sixth nominated for 2026.

• Chair and CEO roles separated in January 2024 to enhance accountability.

• Majority voting standard adopted for uncontested director elections; plurality for contested elections.

• Extensive shareholder engagement, including meetings with holders of 97.4% of shares.